Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Macrogenics (MGNX) Research & Development (2016 - 2025)

Macrogenics (MGNX) has disclosed Research & Development for 13 consecutive years, with $34.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 12.64% to $34.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $147.2 million, a 16.94% decrease, with the full-year FY2025 number at $147.2 million, down 16.94% from a year prior.
  • Research & Development was $34.0 million for Q4 2025 at Macrogenics, up from $32.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $61.4 million in Q1 2022 to a low of $30.1 million in Q3 2023.
  • A 5-year average of $45.6 million and a median of $46.0 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: crashed 37.47% in 2023, then skyrocketed 34.56% in 2024.
  • Macrogenics' Research & Development stood at $55.9 million in 2021, then decreased by 18.26% to $45.7 million in 2022, then rose by 3.72% to $47.4 million in 2023, then dropped by 17.87% to $38.9 million in 2024, then fell by 12.64% to $34.0 million in 2025.
  • Per Business Quant, the three most recent readings for MGNX's Research & Development are $34.0 million (Q4 2025), $32.7 million (Q3 2025), and $40.8 million (Q2 2025).